Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Fineline Cube Jan 14, 2026
Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma

Fineline Cube Jan 14, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Drug

Tonghua Golden-Horse, UCB Seek China Approvals for Alzheimer’s, Myasthenia Gravis Drugs

Fineline Cube Aug 30, 2024

China’s Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. and Belgium-based UCB (FRA: UNC) are seeking marketing...

Company

Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024

Fineline Cube Aug 30, 2024

Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its...

Company Drug

Doma Biopharmaceutical Receives FDA Clearance for Phase I Trial of EGFR-MET Targeting ADC, DM005

Fineline Cube Aug 30, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a Chinese pharmaceutical firm, has received approval from the U.S....

Company Drug

Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials

Fineline Cube Aug 30, 2024

BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...

Company Deals

AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million

Fineline Cube Aug 30, 2024

QINGDAO—AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced a further investment in its...

Company Medical Device

NMPA Suspends Jeisys Medical Inc.’s Nd:YAG Laser Equipment Over Quality Concerns

Fineline Cube Aug 30, 2024

BEIJING—The National Medical Products Administration (NMPA) of China has issued a notification to immediately suspend...

Company Drug

CNGB Virogin’s VG161 On Track for Breakthrough Designation in China for Advanced Liver Cancer

Fineline Cube Aug 30, 2024

BEIJING—CNGB Virogin, a joint venture between Virogin Biotech and China National Biotec Group, is poised...

Policy / Regulatory

China’s Healthcare Statistics Show Improvements in Life Expectancy and Access to Medical Services

Fineline Cube Aug 30, 2024

BEIJING—The National Health Commission (NHC) of China has published the “China’s Healthcare Statistical Communique 2023,”...

Company

Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1

Fineline Cube Aug 30, 2024

SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first...

Company

Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight

Fineline Cube Aug 30, 2024

HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for...

R&D

American Government Funds Bolster Chinese Inventors’ Patents, According to USPTO Data

Fineline Cube Aug 30, 2024

WASHINGTON—A Reuters investigation into the United States Patent and Trademark Office (USPTO) data has uncovered...

Company

GeneQuantum Appoints Dr. Lingyu Zhu as Chief Business Strategy and Development Officer

Fineline Cube Aug 30, 2024

SUZHOU—GeneQuantum, a leading player in the biotech industry known for its cutting-edge enzymatic site-specific conjugation...

Policy / Regulatory

Jiangxi Healthcare Security Administration Launches Initiative to Widen Drug Availability

Fineline Cube Aug 29, 2024

JIANGXI—In a strategic move to enhance drug accessibility, the Healthcare Security Administration (HSA) bureau of...

Company Legal / IP

China’s Supreme Court Deals Blow to Sanofi’s Aubagio, Confirms Patent Cancellation

Fineline Cube Aug 29, 2024

BEIJING—In a recent development for the pharmaceutical industry, Sanofi’s multiple sclerosis therapy Aubagio (teriflunomide) has...

Company Deals

Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases

Fineline Cube Aug 29, 2024

NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE),...

Company Deals

Sackler-Owned Mundipharma Fails to Secure $1 Billion Valuation for China Unit

Fineline Cube Aug 29, 2024

LONDON—Mundipharma International Ltd., the UK-based pharmaceutical firm with ties to the Sackler family of the...

Company Drug

Sinopharm and Ruidio Pharmaceutical Advance in Priority Review for Innovative Drugs and Vaccines

Fineline Cube Aug 29, 2024

BEIJING—The Center for Drug Evaluation (CDE) has indicated that two Chinese companies, Foshan Ruidio Pharmaceutical...

Company Drug

Jiangsu Simcere and AnDiConBio’s Anti-Influenza Drug ADC189 Doses First Patient in Phase III Study

Fineline Cube Aug 29, 2024

JIANGSU—In a significant development for the pharmaceutical industry, Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096),...

Company Drug

Sino Biopharmaceutical’s Anlotinib-Penpulimab Combo Meets Milestone in Phase III HCC Study

Fineline Cube Aug 29, 2024

HONG KONG—Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced...

Company Deals

Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development

Fineline Cube Aug 29, 2024

CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100...

Posts pagination

1 … 248 249 250 … 609

Recent updates

  • Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
  • Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma
  • Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration
  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Company Drug

Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma

Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.